Resalis Therapeutics Secures $11M Series A Financing to Advance Antisense Oligonucleotide Therapy RES-010 for Obesity

Resalis Therapeutics has deep expertise in the field of ncRNA and RNA-targeted therapies for human health and metabolic disorders. The company’s lead candidate, RES-010, is an antisense oligonucleotide targeting miR-22, a central player in regulating lipid metabolism and energy expenditure. In multiple proof-of-concept studies in both large and small animal models, RES-010 has demonstrated the potential to deliver safe and durable therapeutic effects, either as a standalone treatment or in combination with approved drugs. Resalis Therapeutics plans to initiate a Phase 1 clinical study in the first half of 2024 to evaluate the safety and efficacy of RES-010. RES-010 is patent-protected in the United States, Japan, and China, with a patent application pending in the European Union.